SHANGHAI – Tianjin Cansino Inc., the company behind China's phase II Ebola vaccine, has received a $30 million investment from well-respected health care venture firms Qiming Venture Partners and Lilly Asia Ventures. It marks the second venture capital round for the 6-year-old company; in 2013, it accepted $10 million in a round led by Lilly Asia Ventures. (See BioWorld Today, Oct. 13, 2013.)